Pro-drugs of all non-steroidal anti-inflammatories with free acid function derivatized with an ester group which have the general structural formula given below (I) where A is: aspirin diflunisal benorylate ibufenac diclofenac indomethacin sulindac ketorolac ibuprofen naproxen ketoprofen fenoprofen flurbiprofen mefenamic acid meclof enamic acid flufenamic acid niflumic acid and where in the ester group R can be a sugar (amongst which aldose or ketose pentose or esose selected from a group of D- ...

The novel positively charged pro-drugs of arylanthranilic acids in the general formula (1) 'Structure 1' were designed and synthesized. The compounds of the general formula (1) 'Structure 1' indicated above can be prepared from mefenamic acid meclofenamic acid flufenamic acid niflumic acid flunixin and related compounds by reaction with suitable alcohols thiols or amines and coupling reagents such as N N'-Dicyclohexylcarbodiimide N N'-Diisopropylcarbodiimide O-(Benzotriazol-1-yl)-NNN'N'-tetramet...

Pro-drugs of all non-steroidal anti-inflammatories with free acid function derivatized with an ester group which have the general structural formula given below (I) where A is: aspirin diflunisal benorylate ibufenac diclofenac indomethacin sulindac ketorolac ibuprofen naproxen ketoprofen fenoprofen flurbiprofen mefenamic acid meclof enamic acid flufenamic acid niflumic acid and where in the ester group R can be a sugar (amongst which aldose or ketose pentose or esose selected from a group of D- ...

PURPOSE: A GABA(gamma-aminobutyric acid) release inhibitor containing bestrophin 1 channel inhibitor is provided to enable effective and various treatment for GABA-associated disease symptom. CONSTITUTION: A composition for preventing or treating diseases or symptom due to GABA excessive release contains bestrophin 1 channel inhibitor as an active ingredient. The composition suppresses GABA release in the bovine cerebellum. The bestrophin 1 channel inhibitor is an antisense RNA or shRNA of a nuc...

Pro-drugs of all non-steroidal anti-inf lammatories with free acid function derivatized with an ester group which have the general structural formula given below (I) where A is: aspirin diflunisal benorylate ibufenac diclofenac indomethacin sulindac ketorolac ibuprofen naproxen ketoprofen fenoprofen flurbiprofen mefenamic acid meclof enamic acid flufenamic acid niflumic acid and where in the ester group R can be a sugar (amongst which aldose or ketose pentose or esose selected from a group of D-...

PURPOSE: A sustained release tablet containing niflumic acid is provided to enhance release rate of the niflumic acid and treatment effect. CONSTITUTION: A pharmaceutical formulation containing niflumic acid contains niflumic acid and solide dispersion of water soluble polymer. The water soluble polymer is polyvinylpyrrolidone. The content of the polyvinylpyrrolidone is 0.2~1.5 weight parts. The pharmaceutical formulation is hydroxypropylmethylcellulose polymethacrylate or sustained release tabl...